Vaccine

IMUNON to Host R&D Day on September 18th

R&D Discussion in New York City to Review IL-12’s Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders,…

4 months ago

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Figure: 1 Elements of Ocean Biomedical Multi-pronged Malaria Program Testing Result Figure: 2 Dr. Jonathan Kurtis conducting research near Kisumu,…

4 months ago

World-Renowned Scientist Wah Chiu, Stanford University Professor and Honorary Advisor to Pohang City, visited Korea at the invitation of the Coree Group

- Seminar presentation at the invitation of Dx&Vx and Coree Group SEOUL, South Korea, Aug. 26, 2024 /PRNewswire/ -- Professor Wah…

4 months ago

MPOX is Emerging as a Global Threat – NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…

4 months ago

Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding…

4 months ago

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has…

4 months ago

WORK Medical Technology Group LTD Announces Pricing of Initial Public Offering

Hangzhou, China, Aug. 23, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (the "Company"), a supplier of medical devices…

4 months ago

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna’s COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from…

4 months ago

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2

Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following…

4 months ago